Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal
Source: SeekingAlpha
2026-01-21 08:05:54 ET
More on Lisata Therapeutics
- Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript
- Lisata outlines Phase III certepetide trial preparations and targets milestone-rich 2026 amid expanded alliances
- Seeking Alpha’s Quant Rating on Lisata Therapeutics
- Historical earnings data for Lisata Therapeutics
- Financial information for Lisata Therapeutics
Read the full article on Seeking Alpha
For further details see:
Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal
Lisata Therapeutics Inc.
NASDAQ: LSTA
LSTA Trading
-0.1% G/L:
$5.03 Last:
28,071 Volume:
$5.05 Open:
LSTA Latest News
March 06, 2026 06:15:05 pm
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
February 11, 2026 08:02:00 pm
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
January 28, 2026 06:41:00 pm
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
January 27, 2026 08:00:00 am
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
LSTA Stock Data
$40,046,128
7,973,943
3.36%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
Basking Ridge
